Riociguat for pulmonary arterial hypertension associated with congenital heart disease

OBJECTIVE: The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Heart
Autori principali: Rosenkranz, Stephan, Ghofrani, Hossein-Ardeschir, Beghetti, Maurice, Ivy, Dunbar, Frey, Reiner, Fritsch, Arno, Weimann, Gerrit, Saleh, Soundos, Apitz, Christian
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2015
Soggetti:
Pulmonary Vascular Disease
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4680166/
https://ncbi.nlm.nih.gov/pubmed/26135803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heartjnl-2015-307832
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi